Made Scientific

Executive Summary

Made Scientific is a cell therapy contract development and manufacturing organization (CDMO) headquartered in Salt Lake City, Utah, and operating as a subsidiary of GC Corporation. The company offers end-to-end services spanning process and analytical development, GMP and non-GMP manufacturing, aseptic fill/finish, quality control, and regulatory support. Its primary focus is enabling clients to progress cell therapy candidates from pre-clinical stages through commercial manufacturing. As a privately held entity with no disclosed funding rounds, Made Scientific leverages its parent company's resources to invest in cutting-edge facilities and expertise. The cell therapy CDMO market is experiencing robust growth driven by increasing pipeline complexity and outsourcing demand, positioning Made Scientific to capture opportunities despite its pre-clinical stage status. Looking ahead, Made Scientific's growth trajectory hinges on expanding its manufacturing capacity, securing new client contracts, and differentiating through specialized services. The company faces competition from established CDMOs like Lonza, Catalent, and Thermo Fisher, but its focus on cell therapy and backing from GC Corporation provide a strategic advantage. Key risks include slower-than-expected market adoption of cell therapies, regulatory challenges, and potential capacity underutilization. However, the overall tailwind from cell therapy innovation supports a positive long-term outlook. Made Scientific's ability to demonstrate reliable GMP manufacturing and efficient process development will be critical in converting pipeline interest into recurring revenue.

Upcoming Catalysts (preview)

• Q4 2026Announcement of GMP manufacturing facility expansion65% success
• Q2 2027Strategic partnership with a top-10 cell therapy developer45% success
• 2027First commercial manufacturing contract for a late-stage client35% success